Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease

Clinical and Experimental Nephrology

Volumn 19, Issue 2, 2015, Pages 247-253

  Hoshino, Taro ^a   Ookawara, Susumu ^a   Miyazawa, Haruhisa ^a   Ito, Kiyonori ^a   Ueda, Yuichiro ^a   Kaku, Yoshio ^a   Hirai, Keiji ^a   Mori, Honami ^a   Yoshida, Izumi ^a   Tabei, Kaoru ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Hypertension; Loop diuretics; Proteinuria; Thiazides; Type 2 diabetic kidney disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZOSEMIDE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; SULFANILAMIDE DERIVATIVE; URINARY TRACT AGENT;

AGED; BLOOD PRESSURE; COMPLICATION; DIABETIC NEPHROPATHY; DRUG COMBINATION; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEINURIA; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIURETICS; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROTEINURIA; RENAL AGENTS; RETROSPECTIVE STUDIES; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SULFANILAMIDES;

EID: 84939891505     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-0981-2     Document Type: Article

References (27)

1. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamamoto T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y. An overview of regular dialysis treatment in Japan. Ther Apher Dial. 2012;16:483–521.
2. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34:S11–61.
3. Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;. doi:10.1002/14651858.
4. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.
5. Unsal A, Koc Y, Basturk T, Akgun AO, Sakaci T, Ahbap E. Risk factors for progression of renal disease in patient with diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2012;16:878–83.
6. Zoppini G, Targher G, Chonchol M, Ortada V, Negri C, Stoico V, Bonora E. Predicted of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.
7. Altemtam N, Russell J, Nahas ME. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant. 2012;27:1847–54.
8. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342–60.
9. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs. hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant. 2005;20:349–53.
10. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens. 2012;14:32–7.
11. Japan Nephrology Society. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012;54:1034–191 (special issue).
12. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985;27:58–65.
13. Reubi FC, Coottier PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation. 1961;23:200–10.
14. Fujihara CK, Malheiros DMAC, Zatz R. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol Renal Physiol. 2007;292:F1810–8.
15. Fanelli C, Fernandes BH, Machado FG, Okabe C, Malheiros DM, Fujihara CK, Zatz R. Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation. Am J Physiol Renal Physiol. 2011;301:F580–7.
16. O’Grady P, Yee KF, Lins R, Mangold B. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1999;48:375–81.
17. Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol. 1983;24:661–5.
18. Fliser D. Loop diuretics and thiazides—the case for their combination in chronic renal failure. Nephrol Dial Transplant. 1996;11:408–23.
19. Abe M, Okada K, Maruyama T, Matsumoto S, Matsumoto K. Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther. 2010;48:206–13.
20. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19:3033–42.
21. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, Van ZP, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertension. 2007;25:1105–87.
22. Arias SC, Valente CP, Machado FG, Fanelli C, Origassa CS, de Brito T, Camara NO, Malheiros DM, Zatz R, Fujihara CK. Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy. PLoS One. 2013;8:e56215. doi:10.1371/journal.pone.0056215.
23. Farbakhsh K, Kasiske BL. Dyslipidemia in patients who have chronic kidney disease. Med Clin N Am. 2005;89:689–99.
24. Haaber AB, Kofoed-Enevoldsen A, Jensen T. The prevalence of hypercholesterolaemia and its relationship with albuminuria in insulin-dependent diabetic patients: an epidemiological study. Diabet Med. 1992;9:557–61.
25. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008;3:S3–10.
26. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005;99:S87–93.
27. 2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342–53.